NCT06254118 is a Phase 4 clinical trial of Polyunsaturated Fatty Acids in Menopausal Patients, sponsored by Hadir F. El-Dessouky.

Who is sponsoring NCT06254118?

NCT06254118 is sponsored by Hadir F. El-Dessouky.

What drugs are being tested in NCT06254118?

Interventions in NCT06254118: Polyunsaturated Fatty Acids, olive oil.

What condition does NCT06254118 study?

NCT06254118 studies Menopausal Patients, Chronic Periodontitis, Omega 3 Fatty Acids.

Is NCT06254118 still recruiting?

NCT06254118 is currently completed. Last updated 12 February 2024.

Last reviewed 2024-02-12 · How we verify

NCT06254118

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Periodontitis in Menopausal Patients

Completed Phase 4 Last updated 12 February 2024

What this trial tests

Phase 4 trial testing Polyunsaturated Fatty Acids in Menopausal Patients in 20 participants. Completed in 30 January 2023.

Timeline

22 January 2020

Primary endpoint
22 January 2022

30 January 2023

Quick facts

Lead sponsor	Hadir F. El-Dessouky
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	20
Start date	22 January 2020
Primary completion	22 January 2022
Estimated completion	30 January 2023
Sites	1 location across Saudi Arabia

Drugs / interventions tested

Polyunsaturated Fatty Acids — full drug profile →
olive oil — full drug profile →

Conditions studied

Menopausal Patients — all drugs for Menopausal Patients →
Chronic Periodontitis — all drugs for Chronic Periodontitis →
Omega 3 Fatty Acids — all drugs for Omega 3 Fatty Acids →

Sponsor

Hadir F. El-Dessouky — full company profile →

Who can join

Adults 45 to 55, female only, with Menopausal Patients or Chronic Periodontitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the effectiveness of polyunsaturated fatty acids (PUFAs) \[omega-3\] as an adjunctive treatment to scaling and root planing for menopausal women with periodontitis versus scaling and root alone as a non- surgical treatment . . The main question it aims to answer is: • to investigate the effect of systemic administration of Omega-3 fatty acids in addition to SRP on clinical periodontal parameters and GCF levels of osteocalcin and AST in menopausal women. Participants will given \* a soft gelatin capsules containing PUFAs to be consumed directly once daily for 12 months along with non-surgical treatment (group2) \*\* a soft gelatin capsules containing olive oil to be consumed directly once daily for 12 months along with non-surgical treatment (group1) Researchers will compare group 1 to group 2 to see if PUFAs has an effect on clinical periodontal parameters and GCF levels of osteocalcin and AST in menopausal women. .

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Nonsurgical Treatment of Periodontitis in Menopausal Patients: A Randomized Control Trial.
Eldessouky HF, Marie M. · · 2024 · cited 2× · PMID 38510979 · DOI 10.1155/2024/6997142

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06254118 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hadir F. El-Dessouky
Last refreshed: 12 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06254118.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing